SCHEDULE: Millennium Entities Reduce Quoin Pharma Stake Below 5%

Integrated Core Strategies (US) LLC and Millennium Management LLC, along with affiliates, reported reducing their beneficial ownership in Quoin Pharmaceuticals Ltd. to 4.6%.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander (collectively, the "Reporting Persons") filed an Amendment No. 1 to Schedule 13G.
• The filing pertains to their beneficial ownership of Ordinary Shares, no par value per share, of Quoin Pharmaceuticals Ltd.
• As of December 31, 2025, the Reporting Persons collectively beneficially owned 2,618,595 Ordinary Shares.
• This aggregate amount represents 4.6% of the class of Quoin Pharmaceuticals Ltd. Ordinary Shares.
• The Reporting Persons ceased to be beneficial owners of more than 5% of the outstanding Ordinary Shares, triggering this amendment.
• The CUSIP number 74907L409 is assigned to the Issuer's American Depositary Shares, with each ADS representing thirty-five Ordinary Shares; no CUSIP is assigned to the Ordinary Shares directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative as a significant institutional investor group has reduced its stake below the 5% reporting threshold, potentially signaling reduced conviction or portfolio reallocation.

Negatives

• A significant institutional investor group, including Millennium Management LLC, has reduced its beneficial ownership in Quoin Pharmaceuticals Ltd. to below the 5% reporting threshold, which could be interpreted as a decrease in conviction or a portfolio reallocation.

Risks

• The reduction in institutional ownership by a notable investment group could lead to decreased investor confidence or increased selling pressure on Quoin Pharmaceuticals Ltd. shares.

Future Outlook

The reporting persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Quoin Pharmaceuticals Ltd., nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Management Comments

• Gil Raviv, Global General Counsel for Integrated Core Strategies (US) LLC, Millennium Management LLC, and Millennium Group Management LLC, signed the filing.
• Israel A. Englander also signed the filing.

Industry Context

StockSavvy.ai notes that institutional investors frequently adjust their positions in public companies based on various factors, including portfolio rebalancing, changes in investment strategy, or evolving market conditions. A reduction below the 5% threshold, as seen in this Schedule 13G/A filing, indicates a significant change in an institutional investor's stake, which can sometimes influence market perception, though it doesn't always reflect a negative outlook on the company's fundamentals.

Stakeholder Impact

• Shareholders may perceive the reduction in institutional ownership as a negative signal, potentially leading to decreased confidence or increased volatility in the stock price.
• The company's management might need to address investor concerns regarding the change in institutional holdings.

Key Dates

Recommendation

The filing indicates a reduction in a significant institutional stake below the 5% threshold. While this suggests reduced conviction from the reporting entities, it does not necessarily imply a fundamental deterioration of Quoin Pharmaceuticals' prospects. Investors should monitor future filings and company performance, but a 'hold' position is warranted given the lack of explicit negative company-specific news.

Keywords

Quoin Pharmaceuticals, QNRX, Schedule 13G, beneficial ownership, institutional ownership, Millennium Management, Integrated Core Strategies, stake reduction, equity investment